Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

Open access
C. Potts, B., X. Albitar, M., C. Anderson, K., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauhan, D., C. Cusack, J., Fenical, W., M. Ghobrial, I., Groll, M., R. Jensen, P., S. Lam, K., K. Lloyd, G., McBride, W., J. McConkey, D., P. Miller, C., T.C. Neuteboom, S., Oki, Y., Ovaa, H., Pajonk, F., G. Richardson, P., M. Roccaro, A., M. Sloss, C., A. Spear, M., Valashi, E., Younes, A., A. Palladino, M.·2011·Current Cancer Drug Targets

Abstract

The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade) for the treatment of relapsed/refractory multiple myeloma (MM) and mantle cell lymphoma, it has become clear that new inhibitors are needed that have a better therapeutic ratio, can overcome inherent and acquired bortezomib resistance and exhibit broader anti-cancer activities. Marizomib (NPI-0052; salinosporamide A) is a structurally and pharmacologically unique β-lactone-γ-lactam proteasome inhibitor that may fulfill these unmet needs. The potent and sustained inhibition of all three proteolytic activities of the proteasome by marizomib has inspired extensive preclinical evaluation in a variety of hematologic and solid tumor models, where it is efficacious as a single agent and in combination with biologics, chemotherapeutics and targeted therapeutic agents. Specifically, marizomib has been evaluated in models for multiple myeloma, mantle cell lymphoma, Waldenstrom's macroglobulinemia, chronic and acute lymphocytic leukemia, as well as glioma, colorectal and pancreatic cancer models, and has exhibited synergistic activities in tumor models in combination with bortezomib, the immunomodulatory agent lenalidomide (Revlimid), and various histone deacetylase inhibitors. These and other studies provided the framework for ongoing clinical trials in patients with MM, lymphomas, leukemias and solid tumors, including those who have failed bortezomib treatment, as well as in patients with diagnoses where other proteasome inhibitors have not demonstrated significant efficacy. This review captures the remarkable translational studies and contributions from many collaborators that have advanced marizomib from seabed to bench to bedside.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/156800911794519716

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 243

Metadata

Authors
C. Potts, B., X. Albitar, M., C. Anderson, K., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauhan, D., C. Cusack, J., Fenical, W., M. Ghobrial, I., Groll, M., R. Jensen, P., S. Lam, K., K. Lloyd, G., McBride, W., J. McConkey, D., P. Miller, C., T.C. Neuteboom, S., Oki, Y., Ovaa, H., Pajonk, F., G. Richardson, P., M. Roccaro, A., M. Sloss, C., A. Spear, M., Valashi, E., Younes, A., & A. Palladino, M.
Venue
Current Cancer Drug Targets
Published
2011-03-01
Volume
11
Issue
3
Pages
254-284
ISSN
1568-0096 (ISSN-L)
OpenAlex
W1975305152
Cited by
243
References
15
FWCI
8.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials. https://app.cochat.ai/papers/10.2174/156800911794519716
The paper
C. Potts, B., X. Albitar, M., C. Anderson, K., Baritaki, S., Berkers, C., Bonavida, B., Chandra, J., Chauhan, D., C. Cusack, J., Fenical, W., M. Ghobrial, I., Groll, M., R. Jensen, P., S. Lam, K., K. Lloyd, G., McBride, W., J. McConkey, D., P. Miller, C., T.C. Neuteboom, S., . . . A. Palladino, M. (2011). Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials. Current Cancer Drug Targets. https://doi.org/10.2174/156800911794519716

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.